Journal article icon

Journal article

Pleural fluid neutrophil extracellular traps are associated with disease severity and risk of one-year mortality in pleural infection. An observational, international, multicohort study (TORPIDS-3)

Abstract:
BACKGROUND: Influx of large numbers of neutrophils is characteristic of pleural infection; however, neutrophil behaviour is understudied. We designed an observational multicohort study with the aims to discover and validate the association between neutrophil extracellular traps (NETs), disease severity, one-year survival, and the extent of sonographic septations. METHODS: We analysed five independent datasets across three countries. The PILOT cohort (UK, n=215) was used as a discovery cohort for the association of NETs with disease severity with validation in four independent cohorts across three countries (UK, Greece, Italy, n=100). The PILOT cohort was further analysed to assess the association of NETs with one-year survival and the development and extent of sonographic septations. A separate cohort (the Oxford-Osler cohort, UK, n=30) was used to assess the relationship between NETs and the need for intrapleural enzyme therapy (IET) as rescue treatment. RESULTS: A ten-unit increase in NETs was associated with 13% higher odds of being into a higher RAPID Score group (OR=1.13, 95% CI: 1.02-1.27, p=0.02), and this association remained robust in the independent validation cohort (OR=1.29, 95% CI: 1.11-1.40, p=0.0005). A ten-unit increase in NETs was also associated with a 15% higher risk of one-year mortality (HR=1.15, 95% CI: 1.01-1.32, p=0.04) independent of the RAPID Score, and a 17% higher likelihood of sonographic septations (OR=1.17, 95% CI: 1.01-1.37, p=0.04). Citrullinated fibrin was associated with septation severity (OR=1.10, 95% CI: 1.04-1.16, p=0.00005). CONCLUSIONS: Pleural fluid NETs are a biomarker of disease severity and one-year mortality, in pleural infection. Future studies are required to assess the combination of NET-targeting strategies in combination with existing treatments.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1183/13993003.00113-2026

Authors

More by this author
Institution:
University of Oxford
Role:
Author
More by this author
Institution:
University of Oxford
Role:
Author
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0009-0002-9965-0240
More by this author
Institution:
University of Oxford
Role:
Author
More by this author
Institution:
University of Oxford
Role:
Author


Publisher:
European Respiratory Society
Journal:
European Respiratory Journal More from this journal
Pages:
2600113-2600113
Publication date:
2026-04-23
Acceptance date:
2026-04-01
DOI:
EISSN:
1399-3003
ISSN:
0903-1936


Language:
English
Keywords:
Pubs id:
2411578
Local pid:
pubs:2411578
Source identifiers:
W7155363726
Deposit date:
2026-04-27
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP